NASDAQ:OMCL - Omnicell Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$55.10 +0.50 (+0.92 %)
(As of 07/22/2018 12:47 PM ET)
Previous Close$55.10
Today's Range$54.00 - $55.40
52-Week Range$39.75 - $57.70
Volume211,304 shs
Average Volume310,937 shs
Market Capitalization$2.14 billion
P/E Ratio306.11
Dividend YieldN/A
Beta0.83
Omnicell logoOmnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

Receive OMCL News and Ratings via Email

Sign-up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
SymbolNASDAQ:OMCL
CUSIP68213N10
Phone650-251-6100

Debt

Debt-to-Equity Ratio0.33
Current Ratio1.68
Quick Ratio1.22

Price-To-Earnings

Trailing P/E Ratio306.11
Forward P/E Ratio39.93
P/E Growth2.54

Sales & Book Value

Annual Sales$716.16 million
Price / Sales2.99
Cash Flow$1.5902 per share
Price / Cash34.65
Book Value$13.64 per share
Price / Book4.04

Profitability

EPS (Most Recent Fiscal Year)$0.18
Net Income$20.60 million
Net Margins4.55%
Return on Equity4.11%
Return on Assets2.15%

Miscellaneous

Employees2,350
Outstanding Shares38,880,000
Market Cap$2,142.18

Omnicell (NASDAQ:OMCL) Frequently Asked Questions

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) issued its quarterly earnings data on Thursday, April, 26th. The company reported $0.29 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.25 by $0.04. The business earned $182.60 million during the quarter, compared to analysts' expectations of $177.49 million. Omnicell had a return on equity of 4.11% and a net margin of 4.55%. The company's revenue was up 22.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.06 earnings per share. View Omnicell's Earnings History.

When is Omnicell's next earnings date?

Omnicell is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Omnicell.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $1.85-$2.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.97. The company issued revenue guidance of $780-$800 million, compared to the consensus revenue estimate of $790.31 million.Omnicell also updated its Q2 guidance to $0.36-$0.42 EPS.

What price target have analysts set for OMCL?

6 equities research analysts have issued twelve-month price targets for Omnicell's stock. Their predictions range from $44.00 to $63.00. On average, they anticipate Omnicell's share price to reach $56.00 in the next year. This suggests a possible upside of 1.6% from the stock's current price. View Analyst Ratings for Omnicell.

What is the consensus analysts' recommendation for Omnicell?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Omnicell stock?

Here are some recent quotes from research analysts about Omnicell stock:
  • 1. Cantor Fitzgerald analysts commented, "On Monday, April 2, CNBC.com reported that Walmart and perhaps Amazon were looking to acquire PillPack." (4/3/2018)
  • 2. According to Zacks Investment Research, "Omnicell’s fourth-quarter 2017 performance was impressive with year-over-year increase in both earnings and revenues. Further, both of the company’s segments witnessed year-over-year growth. We are encouraged to note that the company is working on product innovation through R&D. The company is expected to gain from its recent launches and strategic partnerships. Its recent product launches include the XR2 Automated Central Pharmacy System and the IVX Workflow, IVX Workflow creates a significant technological advancement for sterile compounding workflow processes, enabling pharmacies to safely and efficiently compound and prepare IV doses.Also, improvement in margin is also encouraging. However, a tough competitive landscape acts as a dampener. Over the past month, Omnicell’s shares have been trading below the broader industry." (2/2/2018)

Who are some of Omnicell's key competitors?

Who are Omnicell's key executives?

Omnicell's management team includes the folowing people:
  • Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 61)
  • Mr. Peter J. Kuipers, Exec. VP & CFO (Age 46)
  • Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 54)
  • Mr. Robin G. Seim, Pres of Global Automation & Medication Adherence (Age 58)
  • Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 58)

Has Omnicell been receiving favorable news coverage?

News headlines about OMCL stock have been trending somewhat positive on Sunday, Accern reports. The research group identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Omnicell earned a media sentiment score of 0.24 on Accern's scale. They also gave news articles about the company an impact score of 46.34 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Omnicell's major shareholders?

Omnicell's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Conestoga Capital Advisors LLC (4.72%), Fisher Asset Management LLC (1.11%), Summit Creek Advisors LLC (0.61%), Scout Investments Inc. (0.42%), Pwmco LLC (0.40%) and West Coast Financial LLC (0.29%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Sara J White. View Institutional Ownership Trends for Omnicell.

Which major investors are selling Omnicell stock?

OMCL stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Scout Investments Inc., Municipal Employees Retirement System of Michigan, West Coast Financial LLC, Foundry Partners LLC and Dubuque Bank & Trust Co.. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, Jorge R Taborga, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Robin Gene Seim. View Insider Buying and Selling for Omnicell.

Which major investors are buying Omnicell stock?

OMCL stock was bought by a variety of institutional investors in the last quarter, including Pwmco LLC, Rhenman & Partners Asset Management AB, Conestoga Capital Advisors LLC, Peregrine Capital Management LLC, Summit Creek Advisors LLC and Bank of Montreal Can. View Insider Buying and Selling for Omnicell.

How do I buy shares of Omnicell?

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $55.10.

How big of a company is Omnicell?

Omnicell has a market capitalization of $2.14 billion and generates $716.16 million in revenue each year. The company earns $20.60 million in net income (profit) each year or $0.18 on an earnings per share basis. Omnicell employs 2,350 workers across the globe.

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]


MarketBeat Community Rating for Omnicell (NASDAQ OMCL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  309 (Vote Outperform)
Underperform Votes:  216 (Vote Underperform)
Total Votes:  525
MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe OMCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.